Recent Updates
Recently added Catalysts

Meloxicam

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 24, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment57

FDA Designations

No designations recorded

Clinical trial landscape

Meloxicam · 2 trials · 1 indication

Phase 1 2
NCT00649077Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mgHealthy
COMPLETED30 Analytics
NCT00649675Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mgHealthy
COMPLETED27 Analytics
PHASE1COMPLETED
Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg
HealthyUnlock trial analytics
PHASE1COMPLETED
Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Bioequivalence
within 30 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
1EXPERIMENTALMeloxicam Tablets 15 mg
2ACTIVE_COMPARATORMobic® Tablets 15 mg

Interventions

NameTypeDescription
Meloxicam Tablets 15 mgDRUG15mg, single dose fasting
Mobic® Tablets 15 mgDRUG15mg, single dose fasting
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administrati...

Countries:United States
Unlock Eligibility Criteria